Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 19.60
Change Today -0.20 / -1.01%
Volume 566.1K
BOLT On Other Exchanges
Symbol
Exchange
Tel Aviv
OTC US
As of 9:24 AM 04/26/15 All times are local (Market data is delayed by at least 15 minutes).

bio light israeli life scien (BOLT) Snapshot

Open
$19.80
Previous Close
$19.80
Day High
$19.80
Day Low
$19.50
52 Week High
10/6/14 - $20.40
52 Week Low
09/28/14 - $13.10
Market Cap
102.2M
Average Volume 10 Days
2.4M
EPS TTM
$-0.05
Shares Outstanding
521.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BIO LIGHT ISRAELI LIFE SCIEN (BOLT)

Related News

No related news articles were found.

bio light israeli life scien (BOLT) Related Businessweek News

No Related Businessweek News Found

bio light israeli life scien (BOLT) Details

BioLight Israeli Life Sciences Investments Ltd. engages in the research and development, and in investments in companies in the biomed sector. The company operates through two segments, Glaucoma and Dry Eye Syndrome, and Cancer Diagnostics. The Glaucoma and Dry Eye Syndrome segment develops and markets a nonpenetrating CO2 laser assisted filtration surgery technology for treating glaucoma; develops a kit that analyzes tear fluid for screening and monitoring dry eye syndrome and its treatment by examining the amount and quality of tear fluid; and researches and develops a sub-conjunctival drug insert technology for the controlled release of ophthalmic medications. The Cancer Diagnostics segment developing medical solutions for cancer diagnostics. It develops CellDetect, a diagnostic technology for the detection of cancer cells through discriminate staining of cancer and pre-cancer cells among normal cells for various cancer indications; owns the development rights to an innovative diagnostic kit for identifying carriers of deleterious BRCA mutations, who are at increased risk to develop breast and ovarian cancer; develops a diagnostic kit for the early identification of colorectal cancer (CRC) using a q-PCR based blood test and a differentiating diagnostic test based on a panel of biomarkers, targeted towards CRC patients found eligible for biological therapy that inhibits the EGFR receptor. This segment also develops and commercializes diagnostic kit for detecting a genetic profile that enhances the risk of developing a severe side effect from the use of Bisphosphonate Related Osteonecrosis of the Jaw; and participates in the funding of the NCBI's Nofar study of predictive biochemical-markers for the development of brain metastases from lung cancer. The company was founded in 2005 and is based in Tel Aviv, Israel.

Founded in 2005

bio light israeli life scien (BOLT) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: 798.0K
Chief Financial Officer
Total Annual Compensation: 409.0K
Compensation as of Fiscal Year 2013.

bio light israeli life scien (BOLT) Key Developments

Bio Light Israeli Life Sciences Investments Ltd. Announces First IOPtiMate System Sale in Hungary

Bio Light Israeli Life Sciences Investments Ltd. announced the first sale of the IOPtiMate system to a medical center located in Hungary. The IOPtiMate system is based on CO2 laser technology that enables the performance of a unique filtration surgery to treat glaucoma without penetrating the inner part of the eyeball, thus allowing for substantial reductions in post-operative complications and use of eye drops compared with alternatives. BioLight recently announced a strategic partnership agreement with Rock-One International Holdings Ltd. The agreement will help BioLight maximize its presence in the Chinese market.

Bio Light Israeli Life Sciences Investments Ltd., Special/Extraordinary Shareholders Meeting, Apr 12, 2015

Bio Light Israeli Life Sciences Investments Ltd., Special/Extraordinary Shareholders Meeting, Apr 12, 2015., at 10:00 Israel Standard Time.

BioLight Reports Positive Clinical Study Findings for its TeaRx Diagnostic Parameters for Dry Eye Syndrome

BioLight Life Sciences Investments Ltd. announced the completion of a U.S. clinical study, conducted by Ora Inc.Andover, MA, designed to compare widely used benchmark tests for dry eye with its TeaRx diagnostic parameters that test components of tear film. Positive statistical correlations were identified between TeaRx diagnostic parameters and widely used benchmark tests for dry eye syndrome The TeaRx diagnostic tests are developed by DiagnosTear Ltd., one of BioLight's subsidiaries. In this prospective study consisting of approximately 200 subjects, widely-used benchmark tests for dry eye were compared with the TeaRx™ diagnostic parameters, including Schirmer's test, TFBUT (Tear-Film Break-Up Time), staining of corneal and conjunctival epithelial cell damage and patient questionnaires. The study analysis was based on testing the sample extremes, quartiles 1 and 4, representing those enrolled subjects with larger differences for each metric. This approach resulted in positive statistical correlations that showed many of the predicted trends and correlations between the widely used benchmark tests and the TeaRx™ diagnostic parameters tests which measure tear film components. The positive correlation that was identified between certain TeaRx™ diagnostic parameters and subjective testing standards that are widely used indicates a unique ability for improving the dry eye syndrome diagnosis by objective quantification of measures over subjective evaluation.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BOLT:IT 19.60 -0.20

BOLT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BOLT.
View Industry Companies
 

Industry Analysis

BOLT

Industry Average

Valuation BOLT Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIO LIGHT ISRAELI LIFE SCIEN, please visit www.bio-light.co.il. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.